Skip to content
VIDEO

Unlocking the key to leukaemia progression in kids

Team

June 2022

Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease

Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse.

Children's Cancers Published research Infectious Diseases Infectious Diseases Epidemiology Leukaemia Translational Research Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases
May 2022

Antifungal use in children with acute leukaemia: state of current evidence and directions for future research

Invasive fungal disease (IFD) remains a common and serious complication in children treated for leukaemia. Antifungal prescription in children with leukaemia presents unique challenges, particularly due to variation in IFD risk between and within leukaemia treatment protocols, drug toxicities and interactions between antifungals and chemotherapeutic agents.

Children's Cancers Published research Infectious Diseases Epidemiology Leukaemia Translational Research Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases
May 2022

The Bone Marrow Microenvironment in B-Cell Development and Malignancy

B lymphopoiesis is characterized by progressive loss of multipotent potential in hematopoi-etic stem cells, followed by commitment to differentiate into B cells, which mediate the humoral response of the adaptive immune system.

Children's Cancers Published research Leukaemia Translational Research
February 2022

COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement

The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.

Children's Cancers Published research Immunisation Infectious Diseases Infectious Diseases Epidemiology Vaccine Trials Group Brain Tumour Research Leukaemia Translational Research Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases COVID-19